Conditions:   Advanced Gastric Cancer;   Gastro-esophageal Junction Cancer
Interventions:   Drug: AUY922;   Drug: Docetaxel or Irinotecan
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting - verified March 2010

Condition:   Gastro-Intestinal Cancer
Interventions:   Drug: 5-FU;   Drug: Leucovorin;   Drug: 5-FU;   Drug: Irinotecan;   Drug: Brivanib;   Drug: Brivanib;   Drug: Brivanib
Sponsor:   Bristol-Myers Squibb
Recruiting - verified March 2010

Condition:   Colorectal Neoplasms
Interventions:   Behavioral: Stepped CRCS Interventions;   Behavioral: Control
Sponsors:   The University of Texas Health Science Center, Houston;   Duke University;   Boston University
Recruiting - verified March 2010

Conditions:   Head and Neck Cancer;   Lung Cancer;   Liver Cancer;   Rectal Cancer;   Cervical Cancer
Intervention:   Drug: [F 18]HX4
Sponsor:   Siemens Molecular Imaging
Recruiting - verified February 2010

Condition:   Colorectal Cancer
Intervention:   Dietary Supplement: vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)
Sponsor:   Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010

Conditions:   Stage IV Colorectal Cancer;   Dignity Therapy
Intervention:   Behavioral: Dignity Therapy
Sponsor:   Northwestern University
Not yet recruiting - verified February 2010

Conditions:   Crohn's Disease;   Rheumatoid Arthritis
Intervention:  
Sponsors:   University of California, San Diego;   Organization of Teratology Information Specialists (OTIS);   Abbott
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Behavioral: Multimedia Education;   Behavioral: Print Media;   Behavioral: Usual and customary waiting room process
Sponsors:   Saint Francis Care;   American Cancer Society;   Feinberg School of Medicine, Northwestern University
Recruiting - verified February 2010

Condition:   Enteritis
Intervention:   Drug: DOR201 (delayed release beclomethasone dipropionate)
Sponsors:   Soligenix;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: ARQ 197 + cetuximab + irinotecan;   Drug: Placebo + cetuximab + irinotecan
Sponsor:   Daiichi Sankyo Inc.
Recruiting - verified February 2010

Condition:   Esophageal Cancer
Intervention:   Drug: Fluoro-L-Thymidine
Sponsors:   Columbia University;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Esophageal Cancer
Intervention:   Drug: C11-Choline
Sponsor:   Wake Forest University
Recruiting - verified March 2010

Condition:   Colorectal Neoplasms
Intervention:   Device: Third Eye Retroscope
Sponsor:   Avantis Medical Systems
Recruiting - verified February 2010

Conditions:   Barrett Syndrome;   Barrett's Syndrome;   Barrett's Esophagus;   Barrett Esophagus;   Adenocarcinoma
Interventions:   Device: Standard endoscopic treatment of BE;   Device: pCLE guided endoscopic treatment of BE
Sponsors:   Mauna Kea Technologies;   Cellvizio Inc.
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Intervention:   Drug: Treatment with OSI-906 and/or irinotecan
Sponsor:   University of Colorado, Denver
Recruiting - verified February 2010

Conditions:   Endometrial Cancer;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Liver Cancer;   Lung Cancer;   Ovarian Cancer
Interventions:   Biological: bevacizumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: XELOX regimen;   Drug: capecitabine;   Drug: hydroxychloroquine;   Drug: oxaliplatin;   Other: laboratory biomarker analysis
Sponsors:   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
Recruiting - verified August 2009

Condition:   Colorectal Cancer
Intervention:   Drug: cetuximab with irinotecan
Sponsor:   Roswell Park Cancer Institute
Recruiting - verified February 2010

Conditions:   Carcinoma, Hepatocellular;   Liver Diseases;   Neoplasms by Histologic Type;   Digestive System Neoplasms;   Carcinoma;   Liver Neoplasms;   Neoplasms;   Neoplasms by Site;   Digestive System Diseases;   Adenocarcinoma;   Neoplasms, Glandular and Epithelial
Interventions:   Drug: ABT-869;   Drug: Sorafenib
Sponsors:   Abbott;   Genentech
Recruiting - verified January 2010

Conditions:   Colonic Polyps;   Colonic Neoplasms
Intervention:   Device: CT colonography and optical colonoscopy
Sponsor:   Japanese CT Colonography Society
Recruiting - verified October 2009

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Gastric Cancer
Interventions:   Drug: FOLFOX regimen;   Drug: Hedgehog antagonist GDC-0449;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: placebo
Sponsors:   New York Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Familial Adenomatous Polyposis
Interventions:   Drug: eflornithine (DFMO);   Drug: acetylsalicylic acid (aspirin);   Other: placebo;   Other: laboratory biomarker analysis;   Other: gene expression analysis;   Other: telephone-based intervention;   Other: immunohistochemistry staining method;   Other: reverse transcriptase-polymerase chain reaction;   Other: protein expression analysis
Sponsor:   Mayo Clinic
Recruiting - verified March 2010

Conditions:   Colorectal Neoplasms;   Lung Neoplasms;   Breast Neoplasms;   Prostatic Neoplasms;   Sarcoma
Interventions:   Drug: figitumumab;   Drug: pegvisomant
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Head and Neck Cancer;   Breast Cancer;   Non-small Cell Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Esophageal Cancer;   Gliomas
Intervention:   Drug: 177Lu-J591
Sponsor:   Weill Medical College of Cornell University
Recruiting - verified March 2010

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer;   Gastric Cancer
Interventions:   Drug: capecitabine;   Drug: docetaxel;   Drug: fluorouracil;   Drug: oxaliplatin
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Oral Mucositis
Interventions:   Biological: AG013;   Biological: AG013;   Biological: AG013;   Other: Placebo;   Other: Placebo;   Other: Placebo
Sponsor:   ActoGeniX N.V.
Recruiting - verified February 2010

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: EZN-2208, Cetuximab and Irinotecan
Sponsor:   Enzon Pharmaceuticals, Inc.
Recruiting - verified March 2010

Conditions:   Gastric Cancer;   Adenocarcinoma
Interventions:   Biological: IMC-1121B;   Other: Placebo;   Other: Best Supportive Care
Sponsor:   ImClone LLC
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Intervention:   Drug: olaparib
Sponsors:   AstraZeneca;   Aptium Oncology Gastrointestinal Cancer Consortium
Recruiting - verified February 2010

Conditions:   Anal Cancer;   Carcinoma of the Appendix;   Colorectal Cancer;   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Gastric Cancer;   Gastrointestinal Carcinoid Tumor;   Liver Cancer;   Nausea and Vomiting;   Pancreatic Cancer;   Peritoneal Cavity Cancer;   Small Intestine Cancer
Interventions:   Drug: palonosetron hydrochloride;   Other: placebo
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Colorectal Cancer;   Head and Neck Cancer;   Neoplasm Metastasis
Interventions:   Drug: BMS-754807;   Drug: cetuximab (Erbitux®)
Sponsor:   Bristol-Myers Squibb
Recruiting - verified November 2009

Conditions:   Stomach Neoplasms;   Esophageal Neoplasms
Interventions:   Drug: BMS-833923;   Drug: Cisplatin;   Drug: Capecitabine
Sponsors:   Bristol-Myers Squibb;   Exelixis
Recruiting - verified December 2009

Conditions:   Cancer;   Colon Cancer;   Colorectal Cancer;   Fever;   Locally Advanced;   Metastatic Colorectal Cancer;   Neutropenia;   Rectal Cancer
Interventions:   Drug: Pegfilgrastim;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Conditions:   Lymphoma;   Small Intestine Cancer
Interventions:   Procedure: radionuclide imaging;   Procedure: single photon emission computed tomography;   Radiation: indium In 111-labeled autologous peripheral blood mononuclear cells;   Radiation: indium In 111-labeled autologous polymorphonuclear leukocytes
Sponsors:   Holden Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2007

Conditions:   Breast Cancer;   Hypercalcemia of Malignancy;   Colon Cancer;   Endocrine Cancer;   Head and Neck Cancer;   Kidney Cancer;   Lung Cancer;   Lymphoma;   Metastatic Cancer;   Multiple Myeloma;   Parathyroid Neoplasms;   Renal Cancer;   Thyroid Cancer;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Non-small Cell Lung Cancer
Intervention:   Drug: denosumab
Sponsor:   Amgen
Recruiting - verified March 2010

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions:   Drug: capecitabine;   Drug: sunitinib malate
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: CT-011;   Drug: FOLFOX
Sponsor:   CureTech Ltd
Recruiting - verified February 2010

Condition:   Gastrointestinal Stromal Tumor (GIST)
Intervention:   Drug: imatinib mesylate
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2010

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: APO2L/TRAIL;   Drug: bevacizumab;   Drug: FOLFOX regimen
Sponsor:   Genentech
Recruiting - verified March 2010

Conditions:   Gastric Cancer;   Stomach Cancer
Intervention:   Drug: Induction including Cetuximab/ surgery/ chemoradiation
Sponsors:   New York University School of Medicine;   Bristol-Myers Squibb;   ImClone LLC
Recruiting - verified February 2010

Condition:   Colorectal Cancer (CRC)
Interventions:   Drug: Irinotecan;   Drug: 5-Fluorouracil (bolus);   Drug: 5-Fluorouracil (infusional);   Drug: Leucovorin calcium;   Drug: CT-322;   Drug: Bevacizumab;   Drug: Bevacizumab Placebo (saline solution)
Sponsor:   Bristol-Myers Squibb
Recruiting - verified January 2010

Conditions:   Colon Cancer;   Rectal Cancer
Interventions:   Biological: Cetuximab;   Drug: Irinotecan;   Biological: IMC-A12
Sponsors:   ImClone LLC;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified February 2010

Conditions:   Ovarian Neoplasms;   Pancreatic Neoplasms;   Colorectal Neoplasms;   Head and Neck Neoplasms;   Lung Neoplasms
Intervention:   Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
Sponsor:   Centocor, Inc.
Recruiting - verified February 2010

Conditions:   Metastatic;   Colorectal Cancer
Interventions:   Drug: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin);   Drug: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Sponsors:   Bayer;   Onyx Pharmaceuticals
Recruiting - verified February 2010

Condition:   Metastatic Colorectal Cancer
Interventions:   Biological: AMG 479;   Other: Placebo;   Other: FOLFIRI;   Biological: AMG 655
Sponsor:   Amgen
Recruiting - verified March 2010

Conditions:   Colon Cancer;   Colorectal Cancer;   Gastrointestinal Cancer;   Metastatic Colorectal Cancer;   Rectal Cancer
Interventions:   Drug: Panitumumab + AMG 102;   Drug: Panitumumab + AMG 479;   Drug: AMG 479;   Drug: AMG 102;   Drug: Panitumumab
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Gastrointestinal Stromal Tumor (GIST)
Interventions:   Drug: Nilotinib (AMN107);   Drug: imatinib (STI571)
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified February 2010

Conditions:   Colon Cancer;   Colorectal Cancer;   Rectal Cancer;   Metastatic Colorectal Cancer
Interventions:   Drug: Panitumumab;   Drug: Bevacizumab;   Drug: mFOLFOX6
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: Sorafenib
Sponsors:   Accelerated Community Oncology Research Network;   Bayer
Recruiting - verified February 2010

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions:   Biological: panitumumab;   Drug: cisplatin;   Drug: docetaxel;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
Sponsors:   American College of Surgeons;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Rectal Cancer
Interventions:   Drug: Curcumin;   Drug: Placebo;   Radiation: Radiotherapy;   Drug: Capecitabine
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified February 2010

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions:   Drug: docetaxel;   Drug: oxaliplatin;   Drug: vandetanib;   Other: placebo
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Renal Cell Carcinoma;   Non-small Cell Lung Cancer;   Malignant Melanoma;   Epithelial Ovarian Cancer;   Colorectal Adenocarcinoma
Intervention:   Biological: MDX-1105
Sponsor:   Bristol-Myers Squibb
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Procedure: therapeutic conventional surgery;   Procedure: therapeutic laparoscopic surgery
Sponsors:   American College of Surgeons;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Esophagogastric Junction Adenocarcinoma;   Gastric Cancer;   Esophageal Cancer
Interventions:   Drug: Capecitabine;   Drug: Epirubicin;   Drug: AMG 102;   Drug: Cisplatin
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Drug: IMO-2055;   Drug: Cetuximab;   Drug: FOLFIRI
Sponsor:   EMD Serono
Recruiting - verified March 2010

Conditions:   Rectal Cancer;   Rectum
Interventions:   Behavioral: questionnaires;   Behavioral: CSI-SH- Cancer Survivorship Intervention
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Albert Einstein College of Medicine of Yeshiva University;   Mount Sinai School of Medicine;   M.D. Anderson Cancer Center;   National Institutes of Health (NIH)
Recruiting - verified February 2010

Conditions:   Breast Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Lung Cancer;   Malignant Mesothelioma;   Pancreatic Cancer;   Prostate Cancer;   Sarcoma
Interventions:   Drug: cisplatin;   Drug: pemetrexed disodium;   Drug: sorafenib tosylate
Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: cetuximab;   Drug: capecitabine;   Drug: oxaliplatin;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Procedure: neoadjuvant therapy;   Procedure: therapeutic surgical procedure;   Radiation: radiation therapy
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   ErbB2 (HER2) Amplified Gastric;   Esophageal;   or Gastro-esophageal Junction Adenocarcinoma That is Unresectable Due to Locally Advanced Metastatic, or Locally Recurrent Disease.
Intervention:   Drug: Lapatinib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Conditions:   Head and Neck Cancer;   Lymphoma;   Lymphoproliferative Disorder;   Nonneoplastic Condition;   Small Intestine Cancer
Intervention:   Biological: TGF-beta-resistant LMP-specific cytotoxic T-lymphocytes
Sponsors:   Baylor College of Medicine;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Lymphoma;   Lymphoproliferative Disorder;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: pazopanib hydrochloride;   Other: pharmacological study
Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
Recruiting - verified January 2010

Conditions:   Head and Neck Cancer;   Lymphoma;   Lymphoproliferative Disorder;   Nonneoplastic Condition;   Small Intestine Cancer
Interventions:   Biological: allogeneic LMP1-/LMP2- specific cytotoxic T-lymphocytes;   Biological: autologous LMP1-/LMP2- specific cytotoxic T-lymphocytes
Sponsor:   Baylor College of Medicine
Recruiting - verified June 2009

Condition:   Esophageal Cancer
Interventions:   Biological: cetuximab;   Drug: cisplatin;   Drug: paclitaxel;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Intervention:   Device: Third Eye Retroscope Auxiliary Imaging System
Sponsors:   M.D. Anderson Cancer Center;   Avantis Medical Systems
Recruiting - verified March 2010

Condition:   Rectal Cancer
Intervention:   Behavioral: Questionnaire
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: Hsp90 inhibitor SNX-5422 mesylate;   Other: flow cytometry;   Other: high performance liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 2009

Condition:   Colorectal Cancer
Intervention:   Behavioral: Questionnaire
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified March 2010

Conditions:   Liver Cancer;   Lymphoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: dasatinib;   Other: pharmacological study
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Colorectal Cancer
Interventions:   Drug: Enzastaurin;   Drug: Placebo;   Drug: Leucovorin;   Drug: 5-FU;   Drug: Bevacizumab
Sponsors:   Eli Lilly and Company;   Roche Pharma AG
Recruiting - verified February 2010

Condition:   Metastatic Colorectal Cancer (MCRC)
Interventions:   Drug: Cetuximab;   Drug: Irinotecan;   Drug: Brivanib;   Drug: Brivanib;   Drug: Brivanib Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified February 2010

Condition:   Adenomatous Polyposis Coli
Interventions:   Drug: Celecoxib;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2010

Conditions:   Barrett's Esophagus;   Esophageal Neoplasms
Intervention:  
Sponsors:   Kansas City Veteran Affairs Medical Center;   TAP Pharmaceutical Products Inc.
Recruiting - verified February 2010

Conditions:   Barrett's Esophagus;   Neoplasms;   Gastroesophageal Reflux
Intervention:  
Sponsor:   Kansas City Veteran Affairs Medical Center
Recruiting - verified February 2009

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Secondary Myelofibrosis;   Small Intestine Cancer
Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Condition:   Colorectal Cancer
Interventions:   Drug: cediranib maleate;   Drug: irinotecan hydrochloride
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Intervention:   Drug: Aspirin
Sponsor:   University of California, Irvine
Recruiting - verified March 2010

Conditions:   Esophageal Cancer;   Adenocarcinoma of the Esophagus;   Squamous Cell Carcinoma
Interventions:   Drug: OncoGel (Paclitaxel gel);   Drug: cisplatin;   Drug: 5-FU;   Radiation: radiation therapy;   Procedure: esophageal resection
Sponsor:   Protherics
Recruiting - verified March 2010

Conditions:   Barrett's Esophagus;   Early Esophageal Adenocarcinoma
Intervention:   Biological: Biopsy
Sponsor:   Mayo Clinic
Recruiting - verified March 2010

Conditions:   Barrett's Esophagus;   Early Esophageal Adenocarcinoma
Intervention:  
Sponsor:   Mayo Clinic
Recruiting - verified March 2010

Conditions:   Barrett's Esophagus;   Gastroesophageal Reflux Disease;   Esophageal Adenocarcinoma
Intervention:  
Sponsor:   Midwest Biomedical Research Foundation
Recruiting - verified February 2009

Conditions:   Lymphoma;   Lymphoproliferative Disorder;   Sarcoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Other: biologic sample preservation procedure;   Other: cytology specimen collection procedure;   Other: immunologic technique;   Procedure: biopsy;   Procedure: study of high risk factors
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified August 2009

Conditions:   Anal Cancer;   Precancerous Condition
Interventions:   Drug: cidofovir;   Genetic: DNA methylation analysis;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Procedure: biopsy;   Procedure: histopathologic examination
Sponsors:   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Prostate Cancer;   Breast Cancer;   Ovarian Cancer;   Lung Cancer;   Gastric Cancer
Intervention:   Drug: Docetaxel plus lonafarnib
Sponsor:   Schering-Plough
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Drug: fentanyl sublingual spray;   Other: questionnaire administration
Sponsor:   Insys Therapeutics Inc
Recruiting - verified October 2008

Conditions:   Gastrointestinal Cancer;   Lung Cancer
Interventions:   Drug: Melatonin;   Drug: Placebo
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified February 2010

Conditions:   Esophageal Cancer;   Lung Cancer
Interventions:   Procedure: 4D CT scans;   Procedure: Lung Function Imaging
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified March 2010

Condition:   Gastrointestinal Stromal Tumors
Intervention:   Other: GIST Registry
Sponsors:   M.D. Anderson Cancer Center;   Novartis Pharmaceuticals
Recruiting - verified March 2010

Conditions:   Hereditary Nonpolyposis Colorectal Cancer;   Lynch Syndrome
Intervention:   Behavioral: Questionnaire
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Drug: 5-FU;   Drug: Cetuximab;   Drug: Dasatinib;   Drug: Leucovorin;   Drug: Oxaliplatin
Sponsors:   M.D. Anderson Cancer Center;   Bristol-Myers Squibb
Recruiting - verified March 2010

Conditions:   Lymphoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: vorinostat;   Other: pharmacological study
Sponsors:   University of Pittsburgh;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   Cancer and Leukemia Group B;   Eastern Cooperative Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Colorectal Neoplasms
Interventions:   Drug: bevacizumab;   Drug: AG-013726;   Drug: AG-013736 (axitinib)
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Lymphoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Biological: bevacizumab;   Drug: cediranib maleate;   Genetic: TdT-mediated dUTP nick end labeling assay;   Other: flow cytometry;   Other: fluorescent antibody technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: biopsy;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Breast Cancer;   Cervical Cancer;   Prostate Cancer;   Colorectal Cancer;   Lung Cancer
Interventions:   Behavioral: Questionnaire;   Behavioral: Patient Navigator (PN)
Sponsors:   M.D. Anderson Cancer Center;   Centers for Medicare and Medicaid Services
Recruiting - verified March 2010

Conditions:   Lymphoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: daniquidone;   Other: pharmacological study
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Esophageal Neoplasms;   Stomach Neoplasms;   Neoplasm Metastasis
Intervention:   Drug: capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
Sponsors:   Duke University;   Hoffmann-La Roche;   Sanofi-Aventis;   Genentech
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Small Intestine Cancer
Interventions:   Drug: everolimus;   Other: laboratory biomarker analysis
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified October 2009

Condition:   Small Intestine Cancer
Interventions:   Drug: capecitabine;   Drug: irinotecan hydrochloride;   Drug: oxaliplatin
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neoplastic Syndrome
Interventions:   Drug: motesanib diphosphate;   Drug: octreotide acetate;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis;   Procedure: computed tomography
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Cancer;   Colon Cancer;   Colorectal Cancer;   Metastatic Cancer;   Rectal Cancer;   Metastatic Colorectal Cancer
Interventions:   Drug: FOLFIRI - Panitumumab;   Drug: FOLFIRI - Bevacizumab
Sponsor:   Amgen
Recruiting - verified February 2010

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Secondary Myelofibrosis;   Small Intestine Cancer
Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2009

Conditions:   Gastric Cancer;   Pancreatic Cancer;   Cervical Cancer;   Vulvar Cancer;   Endometrial Cancer;   Anal Cancer
Interventions:   Behavioral: Interview;   Other: Questionnaire
Sponsors:   M.D. Anderson Cancer Center;   Merck
Recruiting - verified March 2010

Conditions:   Colorectal Neoplasms;   Melanoma;   Prostatic Neoplasms;   Renal Cell Carcinoma;   Neoplasms
Intervention:   Drug: CP-675,206
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Colon Cancer
Intervention:   Behavioral: Questionnaire
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified March 2010

Condition:   Anal Cancer
Interventions:   Biological: cetuximab;   Drug: cisplatin;   Drug: fluorouracil;   Radiation: radiation therapy
Sponsors:   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Esophageal Cancer
Interventions:   Drug: cisplatin;   Drug: irinotecan hydrochloride;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Anal Cancer
Interventions:   Biological: cetuximab;   Drug: cisplatin;   Drug: fluorouracil;   Radiation: radiation therapy
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Lymphoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: gemcitabine hydrochloride;   Drug: triapine
Sponsors:   Arthur G. James Cancer Hospital & Richard J. Solove Research Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2007

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: clinical observation
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Early Stage Esophageal Adenocarcinoma;   Barrett Esophagus
Interventions:   Procedure: Endoscopic Mucosal Resection;   Procedure: photodynamic therapy
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Drug: isolated perfusion;   Drug: melphalan
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 2009

Condition:   Colorectal Cancer
Interventions:   Drug: capecitabine;   Drug: fluorouracil;   Drug: oxaliplatin;   Radiation: radiation therapy
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Oral Complications;   Ovarian Cancer;   Pain;   Sarcoma
Interventions:   Procedure: management of therapy complications;   Procedure: pain therapy
Sponsor:   Medical College of Wisconsin
Recruiting - verified June 2009